Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial.

IF 2 4区 医学 Q3 NUTRITION & DIETETICS
Michelle Sako Omodei, Jackeline Chimicoviaki, Daniel Araujo Brito Buttros, Benedito Souza Almeida-Filho, Carla Priscila Carvalho-Pessoa, Eduardo Carvalho-Pessoa, Heloisa De Luca Vespoli, Eliana Aguiar Petri Nahas
{"title":"Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial.","authors":"Michelle Sako Omodei, Jackeline Chimicoviaki, Daniel Araujo Brito Buttros, Benedito Souza Almeida-Filho, Carla Priscila Carvalho-Pessoa, Eduardo Carvalho-Pessoa, Heloisa De Luca Vespoli, Eliana Aguiar Petri Nahas","doi":"10.1080/01635581.2025.2480854","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to evaluate the effect of vitamin D (VD) supplementation on the pathological complete response (pCR) rate in women with breast cancer (BC) undergoing neoadjuvant chemotherapy (NCT). A randomized clinical trial was conducted with 80 women aged ≥45years with BC who were eligible for NCT. Women were randomized into two groups: VD group, daily supplementation with 2,000IU of cholecalciferol (<i>n</i> = 40) or placebo (<i>n</i> = 40), for 6 months. The primary outcome measure was the pCR rate. Serum 25-hydroxyvitamin-D [25(OH)D] levels were measured after BC diagnosis and the end of NCT. Of the 80 randomized women, 75 completed the NCT and underwent surgery. Baseline 25(OH)D values indicated hypovitaminosis D in both groups (VD: 19.6 ± 5.8 ng/mL and placebo: 21 ± 7.9 ng/mL, <i>p</i> = 0.33). After 6 months, 25(OH)D levels increased in the VD group compared to the placebo group (28 ± 8.7 vs. 20.2 ± 6.1 ng/mL, <i>p</i> = 0.03). The pCR rate was higher in women supplemented with VD when compared than the placebo (43% vs. 24%, <i>p</i> = 0.04). Adjusted logistic regression showed that women with 25(OH)D levels ≥20ng/mL were more likely to achieve pCR (OR3.65, 95%CI 1.09-12.8, <i>p</i> = 0.04). Women with BC undergoing NCT who received supplementation with 2,000IU of VD were more likely to achieve a pathological complete response than women in the placebo group.</p><p><strong>Trial registration: </strong>Ensaiosclinicos.gov.br, identifier RBR-10k4gqdg.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"648-657"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition and Cancer-An International Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01635581.2025.2480854","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to evaluate the effect of vitamin D (VD) supplementation on the pathological complete response (pCR) rate in women with breast cancer (BC) undergoing neoadjuvant chemotherapy (NCT). A randomized clinical trial was conducted with 80 women aged ≥45years with BC who were eligible for NCT. Women were randomized into two groups: VD group, daily supplementation with 2,000IU of cholecalciferol (n = 40) or placebo (n = 40), for 6 months. The primary outcome measure was the pCR rate. Serum 25-hydroxyvitamin-D [25(OH)D] levels were measured after BC diagnosis and the end of NCT. Of the 80 randomized women, 75 completed the NCT and underwent surgery. Baseline 25(OH)D values indicated hypovitaminosis D in both groups (VD: 19.6 ± 5.8 ng/mL and placebo: 21 ± 7.9 ng/mL, p = 0.33). After 6 months, 25(OH)D levels increased in the VD group compared to the placebo group (28 ± 8.7 vs. 20.2 ± 6.1 ng/mL, p = 0.03). The pCR rate was higher in women supplemented with VD when compared than the placebo (43% vs. 24%, p = 0.04). Adjusted logistic regression showed that women with 25(OH)D levels ≥20ng/mL were more likely to achieve pCR (OR3.65, 95%CI 1.09-12.8, p = 0.04). Women with BC undergoing NCT who received supplementation with 2,000IU of VD were more likely to achieve a pathological complete response than women in the placebo group.

Trial registration: Ensaiosclinicos.gov.br, identifier RBR-10k4gqdg.

补充维生素D可改善乳腺癌患者接受新辅助化疗的病理完全缓解:一项随机临床试验
本研究旨在评估补充维生素D (VD)对乳腺癌(BC)新辅助化疗(NCT)患者病理完全缓解(pCR)率的影响。一项随机临床试验对80名年龄≥45岁的BC患者进行了NCT治疗。女性被随机分为两组:VD组,每天补充2000国际单位的胆钙化醇(n = 40)或安慰剂(n = 40),持续6个月。主要结局指标为pCR率。在BC诊断和NCT结束后测定血清25-羟基维生素D [25(OH)D]水平。在80名随机分配的女性中,75名完成了NCT并接受了手术。基线25(OH)D值显示两组维生素D缺乏症(VD: 19.6±5.8 ng/mL,安慰剂:21±7.9 ng/mL, p = 0.33)。6个月后,与安慰剂组相比,VD组25(OH)D水平升高(28±8.7 vs. 20.2±6.1 ng/mL, p = 0.03)。与安慰剂组相比,补充VD组的pCR率更高(43% vs. 24%, p = 0.04)。经校正的logistic回归显示,25(OH)D水平≥20ng/mL的女性更有可能实现pCR (OR3.65, 95%CI 1.09-12.8, p = 0.04)。接受NCT治疗的BC患者在补充2000 iu VD后比安慰剂组更有可能达到病理完全缓解。试验注册:Ensaiosclinicos.gov.br,标识符RBR-10k4gqdg。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.80
自引率
3.40%
发文量
172
审稿时长
3 months
期刊介绍: This timely publication reports and reviews current findings on the effects of nutrition on the etiology, therapy, and prevention of cancer. Etiological issues include clinical and experimental research in nutrition, carcinogenesis, epidemiology, biochemistry, and molecular biology. Coverage of therapy focuses on research in clinical nutrition and oncology, dietetics, and bioengineering. Prevention approaches include public health recommendations, preventative medicine, behavior modification, education, functional foods, and agricultural and food production policies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信